1	Effect of intravenous lidocaine dose on pain upon awakening in pediatric
2	tonsillectomy: A randomized trial
3	
4 5	
6	Yang Hu <sup>#</sup> , Ming-Cheng Du <sup>#</sup> , Yi Chen <sup>#</sup> , Xiang Long, Jing-Jing Jiang, & Yuan Gong <sup>*</sup>
7	
8	
9	Institute of Anesthesiology and Critical Care Medicine, China Three Gorges University &
10	Yichang Central People's Hospital, Yichang City, Hubei Province, China
11	
12	* Corresponding author
13	E-mail: <u>gy-yc@163.com (YG)</u>
14	

<sup>15</sup> # Yang Hu, Ming-Cheng Du, and Yi Chen contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### Abstract 16

17	We investigated the potential of intravenous lidocaine to reduce pain on awakening in a dose-
18	dependent manner and aimed to determine the median effective dose of lidocaine in 200
19	children aged 3-12 years (American Society of Anesthesiologists physical status I-II) who
20	underwent elective tonsillectomy with or without adenoidectomy at Yichang Central People's
21	Hospital. The patients were randomized into four dose groups (A-D: 0.0, 1.0, 1.5, and 2.0
22	mg/kg, respectively), and they underwent the same anesthetic induction and maintenance
23	protocols. The primary outcome was pain on awakening, while secondary outcomes included
24	pain scores at 1, 4, 12, and 24 h after awakening; incidences of laryngospasm, bronchospasm,
25	or perioperative stridor; and time to extubation. Intraoperative cardiac events were classified
26	as safety events. Our findings indicated that intravenous lidocaine dose-dependently reduced
27	pain on awakening, with the median effective dose being 1.75 mg/kg. Significant differences
28	were observed between groups A and D (P $\leq$ 0.001). No incidents of laryngospasm,
29	bronchospasm, or perioperative stridor were observed. Furthermore, there were significant
30	between-group differences in time to extubation ( $P \le 0.05$ ). In conclusion, our study
31	demonstrated that lidocaine dose-dependently reduced pain on awakening in children
32	undergoing tonsillectomy with or without adenoidectomy, with no severe adverse events.
33	Key Words: lidocaine, pediatric patient, tonsillectomy, pain on awakening

34

# 35 Introduction

36	Tonsillectomy, with or without adenoidectomy, is one of the most common surgical
37	procedures performed in children wherein children receive general anesthesia via a tracheal
38	tube [1,2]. Although this surgery is a common and safe procedure in children, severe pain on
39	awakening is frequently observed following pediatric adenotonsillectomy [3]. It can easily
40	turn into persistent pain without appropriate treatment and drastically limits patients' oral
41	intake of fluids and pain medication, potentially extending postoperative length of stay [4,5].
42	Lidocaine is a local anesthetic that is used as a general anesthetic adjunct because of its
43	analgesic, anti-hyperalgesic, anti-inflammatory, and immunomodulatory properties related to
44	stress [6-8]. Intravenous lidocaine reduces pain after elective surgery under general
45	anesthesia [9]. However, it is unclear whether lidocaine reduces pain on awakening in a dose-
46	dependent manner, and the median effective dose (ED <sub>50</sub> ) of intravenous lidocaine in children
47	remains unknown.
48	We hypothesized that intravenous lidocaine reduces pain on awakening in a dose-dependent

We hypothesized that intravenous lidocaine reduces pain on awakening in a dose-dependent manner and determined the ED<sub>50</sub> of lidocaine in children undergoing tonsillectomy with or without adenoidectomy. The choice of pain on awakening as the primary outcome was guided by the need for clinically meaningful outcomes with potential benefits.

# 52 Materials and methods

## 53 Ethical Considerations

All procedures performed in studies involving human participants were in accordance with
the ethical standards of the institutional and/or national research committee and with the 1964

61	Study Design
60	of all children enrolled in the study.
59	September 17, 2021). Written informed consent was obtained from the parents or guardians
58	Central People's Hospital (approval number: HEC-KYJJ-2020-038-02; approval date:
57	design was approved by the Institutional Review Board (president, Ke-Jun Yan) of Yichang
56	Declaration of Helsinki and its later amendments or comparable ethical standards. The study

- 62 This single-center, parallel-group, double-blind, randomized controlled trial (principal
- 63 investigator, Yuan Gong) was registered in the Chinese Clinical Trial Registry
- 64 (<u>http://chictr.org.cn/showproj.aspx?proj=136605</u>) (registration number: ChiCTR2100053006;
- registration date: November 8, 2021). The trial was conducted from December 1, 2021, to
- May 30, 2022, at Yichang Central People's Hospital, Hubei Province, China, in accordance
- with the CONSORT guidelines. Patients were randomized to each group in an equal (1:1:1:1)
- ratio. Randomization was computer-generated, and each patient was assigned a code.

### 69 **Patients**

- 70 The inclusion criteria were patients aged 3–12 years (American Society of Anesthesiologists
- 71 physical status I–II) who were scheduled for elective tonsillectomy with or without
- adenoidectomy. Children were divided into the following four groups, according to the dose
- of lidocaine administered: A (0.0 mg/kg), B (1.0 mg/kg), C (1.5 mg/kg), and D (2.0 mg/kg).
- 74 The exclusion criteria were chronic cough, a history of steroid or bronchodilator treatment,
- reactive airway disease, upper airway infection 2 weeks before the procedure, angiotensin-
- converting enzyme inhibitor therapy, gastroesophageal reflux, morbid obesity, known allergy
- to any of the study drugs, use of medications or nutraceuticals known to affect blood pressure

(BP) and heart rate (HR), surgery lasting > 2 h, unexpected bleeding, and the need for > 2
intubation attempts.

### 80 **Perioperative Anesthetic Care**

Preoperatively, all children fasted for 6 h and were restricted from oral intake of clear fluids 81 for 1 h. The children entered the operating room accompanied by their parents to curb 82 separation anxiety. Non-invasive BP, HR, and pulse oxygen saturation were measured, and 83 electrocardiography was performed using a multifunction monitor (GE Healthcare, Chicago, 84 IL, USA). The width of the BP cuff for each patient was approximately two-thirds of the 85 length of the upper arm. After stabilization for 5 min, baseline HR, systolic BP, diastolic BP, 86 and mean arterial pressure values were obtained from the average of three measurements 87 taken 2 min apart. A 22-gauge intravenous catheter was subsequently inserted into a vein on 88 the back of the hand. 89

After preoxygenation, the drug of interest (lidocaine [Anhui Changijang Pharmaceutical Co. 90 Ltd., Wuhu City, China] or 0.9% saline) was administered intravenously for 3 s. An 91 anesthetic nurse blinded to the study prepared the drug of interest to be administered through 92 an infusion pump. General anesthesia was induced 2 min after administration, using the 93 following induction protocol: sufentanil (0.25 µg/kg [Yichang Renfu Pharmaceutical Co. 94 Ltd., Yichang City, China]), propofol (2.0 mg/kg [Fresenius Kabi Deutschland GmbH, 95 Homburg, Germany]), and rocuronium (0.6 mg/kg [Zhejiang Xianju Pharmaceutical Co. Ltd., 96 Taizhou City, Zhejiang Province, China]). An anesthetist blinded to the study graded the 97 cough response during injection. When the eyelash reflex disappeared, the lungs were 98 ventilated via a face mask with 100% oxygen. A cuffed tracheal tube was used, the size of 99 which was selected based on a widely used formula (3.5 + [age (years)] / 4). The patient was 100

excluded from the study if any difficulty was encountered while performing face mask
ventilation. Anesthesia was maintained with 2–3% sevoflurane (Maruishi Pharmaceutical Co.
Ltd., Osaka, Japan) and 50% oxygen.

At the end of the procedure, sevoflurane was discontinued, and neostigmine (0.04 mg/kg 104 [Zhejiang Xianju Pharmaceutical Co. Ltd.]) and atropine (0.02 mg/kg [Suicheng 105 Pharmaceutical Co. Ltd., Xinzheng City, China]) were administered to antagonize any 106 residual neuromuscular blockade. Following surgery, oral suction was immediately 107 performed, with the patient still under anesthesia. Extubation was performed while the patient 108 recovered after confirming an adequate tidal volume, a regular spontaneous respiratory 109 pattern, and purposeful behavior (eves opened on request). After extubation, an anesthetist 110 who was not involved in the study assessed recovery from anesthesia, scored the throat pain, 111 and graded the cough response. Patients were monitored for  $\geq 5 \text{ min}$ , with 100% oxygen via a 112 face mask, to allow regular spontaneous respiration. Patients were transferred to a post-113 anesthesia care unit (PACU) after extubation. The time to extubation (from sevoflurane 114 discontinuation to tracheal extubation) was recorded. Electrocardiography, peripheral pulse 115 oximetry, and non-invasive BP measurements were also performed. 116

117 Patients were discharged from the PACU when their Steward score was > 4. Other

postoperative care was performed according to the practices of local clinicians. If the pain

119 (Face, Legs, Activity, Cry, and Consolability scale [children aged 3–4 years], Wong-Baker

scale [children aged 4–7 years], or visual analog scale [children aged  $\geq 8$  years])<sup>3</sup> score was  $\geq$ 

121 3 at rest, the attending PACU nurse administered intravenous propacetamol (30 mg/kg) as

treatment. The use of other medications was restricted.

### 123 **Primary Outcome**

6

124 The primary outcome was pain on awakening.

### 125 Secondary Outcomes

- 126 The secondary outcomes were pain scores at 1, 4, 12, and 24 h after awakening; incidences of
- 127 laryngospasm, bronchospasm, and perioperative stridor; and time to extubation. Safety events
- included intraoperative cardiac events (arrhythmia, hypotension [mean arterial pressure < 65
- 129 mmHg], hypertension [mean arterial pressure > 90 mmHg]), and rescue treatment.

### 130 Statistical analyses

- 131 The sample size was calculated based on an expected pain on-awakening score difference of
- 132 1 (clinical significance), with 80% power ( $\alpha = 0.05$ ,  $\beta = 0.2$ ), which indicated that 50 patients
- 133 were required per group. Patient characteristics (including age, height, and weight); pain on
- awakening scores; incidences of laryngospasm, bronchospasm, and perioperative stridor;
- duration of surgery; and time to extubation were expressed as mean  $\pm$  SD and analyzed using
- ANOVA, with a P-value < 0.05 indicating a significant difference. Statistical significance
- 137 was set at P < 0.01. All statistical analyses were conducted using GraphPad Prism (version
- 138 8.0.2; GraphPad Software Inc., San Diego, CA, USA).


# 139 **Results**

### 140 **Patients**

- 141 Between December 1, 2021, and May 30, 2022, 200 patients were enrolled and divided into
- four groups based on the dose of lidocaine administered(Fig. 1). There were significant
- differences in the time to extubation between groups A and B (P = 0.014), A and C (P =
- 144 0.015), and A and D (P = 0.017). Patient characteristics and other operative data were not

significantly different between the groups (Table 1).

### 146 Fig. 1Flow Diagram



147

	Group A <sup>a</sup>	Group B <sup>b</sup>	Group C <sup>c</sup>	Group D <sup>d</sup>	
	(n = 50)	(n = 50)	(n = 50)	(n = 50)	
	5.55 + 2.02	6.02 ±	5.77 ±		
Age (years)	$5.55 \pm 2.02$	2.35	1.91	5.98 ± 1.67	
TT - 1.7 ( )	118.34 ±	$120.60 \pm$	117.81 ±	120.49 ±	
Height (cm)	14.21	16.02	13.65	12.02	
W · 14 / 1		23.57±	22.57 ±	25.03 ±	
Weight (kg)	$22.88 \pm 7.60$	8.57	6.65	7.22	
	15.06 + 2.65	15.75±	$16.04 \pm$	$16.97 \pm$	
Body mass index (kg/m <sup>2</sup> )	$15.96 \pm 2.65$	2.22	2.27	2.75	
Sex (M/F)	26/21	27/20	29/18	29/18	
ASA physical status (I/II)	47/0	47/0	47/0	47/0	
	29.74 ±	$29.40 \pm$	29.43 ±	27.34 ±	
Duration of surgery (min)	11.14	11.10	13.68	11.95	
	11.55 + 2.22	13.72 ±	13.70 ±	13.68 ±	
Time of extubation (min)	$11.55 \pm 3.32$	3.30*	3.59*	3.58*	
Incidence of laryngospasm	0	0	0	0	
Incidence of bronchospasm	0	0	0	0	
Incidence of perioperative stridor	0	0	0	0	
Tonsillectomy with or without	48/2	50/0	50/0	49/1	

## 148 Table 1. Patient characteristics and clinical data


adenoidectomy

- <sup>149</sup> <sup>a</sup>Group A = lidocaine (0.0 mg/kg) intravenously
- $^{b}$ Group B = lidocaine (1.0 mg/kg) intravenously
- 151 °Group C = lidocaine (1.5 mg/kg) intravenously
- <sup>d</sup>Group D = lidocaine (2.0 mg/kg) intravenously
- 153 Values are expressed as n or mean  $\pm$  SD. \*P < 0.05 (compared with Group A). ASA,
- 154 American Society of Anesthesiologists; F, female; M, male

### 155 **Primary outcomes**

- 156 The ED<sub>50</sub> of intravenous lidocaine for pain on awakening was 1.75 mg/kg (Fig. 2a). All 50
- 157 patients in each group were assessed for the primary outcome. The score for pain on
- awakening was significantly different between the groups, in a dose-dependent manner, with
- significant differences between groups C and D (P = 0.037), A and B (P = 0.007), B and D (P
- 160 = 0.003), and A and C (P  $\leq$  0.001). There was also a significant difference between groups A
- 161 and D (P  $\leq$  0.001) (Fig. 2b).

Fig. 2 Intravenous lidocaine for pain on awakening. (a) Concentration-response curve. (b) Pain on awakening scores. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001; \*\*\*\*P < 0.0001. ED<sub>50</sub>, median effective dose.




165

### 166 Secondary outcomes

The pain score at 1 h after awakening was significantly different between groups A and B (P 167  $\leq$  0.001); A, C, and D (P  $\leq$  0.001); and B and D (P = 0.010). The pain score at 4 h after 168 awakening was significantly different between groups A and B ( $P \le 0.001$ ); A, C, and D ( $P \le$ 169 (0.001); and B and D (P = 0.015); however, there were no significant differences in the pain 170 scores at 12 and 24 h after awakening (Fig. 3). No cases of laryngospasm, bronchospasm, or 171 perioperative stridor were observed in any group. However, significant differences in the time 172 to extubation were observed between groups A and B (P = 0.014), A and C (P = 0.015), and 173 A and D (P = 0.017) (Table 1). No severe complications, such as arrhythmia, were observed 174 in any group. 175

176 Fig. 3 Pain scores at 1, 4, 12, and 24 h after awakening.





# 178 **Discussion**

179 Tonsillectomy is one of the most painful surgical procedures. The relief of pain after tonsillectomy remains challenging and controversial. Several interventions have been 180 recommended to control pain after tonsillectomy in children [10]. Opioids are an important 181 treatment strategy for postoperative pain. However, there is a tendency to avoid using 182 narcotics for respiratory depression in children. Large studies of non-steroidal anti-183 inflammatory drugs have demonstrated effective pain management [10]. However, their 184 potential for treatment of more severe bleeding events has been debated. 185 In this trial, intravenous lidocaine resulted in a dose-dependent reduction in pain on 186

- awakening, with an  $ED_{50}$  of 1.75 mg/kg. Even 1 and 4 h after surgery, there was a
- considerable reduction in pain scores for those who received lidocaine compared with those

189	who did not receive lidocaine. Only after 12 h did the pain scores on awakening exhibit no
190	difference between groups. This seems feasible as the duration of surgery was < 1 h and the
191	half-life of intravenous lidocaine was approximately 2 h [11]. The exact inhibitory
192	mechanism of lidocaine is unclear. It may involve its analgesic, anti-hyperalgesic, anti-
193	inflammatory, and immunomodulatory properties related to stress [6-8].
194	No cases of laryngospasm, bronchospasm, perioperative stridor, or other serious
195	complications were observed during anesthesia. Intravenous lidocaine appears safe and does
196	not result in serious adverse events in children. Substantial differences in the time to
197	extubation were observed between the study (B, C, and D) groups and the control (A) group;
198	the time in the control group was 2 min longer to meet extubation requirements.
199	This study has several limitations. First, it was a single-center study, which reduced its power
200	and reliability. Second, we used the sevoflurane concentration in end-expiratory gas to
201	monitor the depth of anesthesia, potentially leading to an increase in the $ED_{50}$ .

# 202 Conclusion

Intravenous lidocaine reduced pain on awakening in children undergoing tonsillectomy with
or without adenoidectomy in a dose-dependent manner without causing serious adverse
events. The ED<sub>50</sub> of intravenous lidocaine for pain on awakening was 1.75 mg/kg.

# 206 Acknowledgments

207 We would like to thank Editage (<u>www.editage.com</u>) for English language editing.

# 208 Conflicts of interest and source of funding

13

### 209 None declared.

# 210 **References**

211	1.	Lerman J. Pedi	atric ambulatory	v anesthesia: a	an update.	Curr Opin	Anaesthesiol
-----	----	----------------	------------------	-----------------	------------	-----------	--------------

212 2019;32:708-713.

Bhattacharyya N, Lin HW. Changes and consistencies in the epidemiology of pediatric
 adenotonsillar surgery, 1996–2006. Otolaryngol Head Neck Surg 2010;143:680-684.

3. Muzzi E, Ronfani L, Bossini B, Lezcano C, Orzan E, Barbi E. Effects of intraoperative
auditory stimulation on pain and agitation on awakening after pediatric

adenotonsillectomy: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg
2021;147:638-645.

# Aldamluji N, Burgess A, Pogatzki-Zahn E, Raeder J, Beloeil H, PROSPECT Working Group collaborators\*, et al. PROSPECT guideline for tonsillectomy: systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia 2021;76:947-961.

5. Constant I, Khalfallah SA, Brunaud A, Deramoudt V, Fayoux P, Giovanni A, et al.

How to replace code after tonsillectomy in children under 12 years of age?

225 Guidelines of the French Oto-Rhino-Laryngology–Head and Neck Surgery Society

(SFORL). Eur Ann Otorhinolaryngol Head Neck Dis 2014;131:233-238.

Hermanns H, Hollmann MW, Stevens MF, Lirk P, Brandenburger T, Piegeler T, et al.
 Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: a
 narrative review. Br J Anaesth 2019;123:335-349.

230	7.	Beaussier M, Delbos A, Maurice-Szamburski A, Ecoffey C, Mercadal L. Perioperative
231		use of intravenous lidocaine. Drugs 2018;78:1229-1246.
232	8.	Foo I, Macfarlane AJR, Srivastava D, Bhaskar A, Barker H, Knaggs R, et al. The use of
233		intravenous lidocaine for postoperative pain and recovery: international consensus
234		statement on efficacy and safety. Anaesthesia 2021;76:238-250.
235	9.	Estebe JP. Intravenous lidocaine. Best Pract Res Clin Anaesthesiol 2017;31:513-521.
236	10.	Barrette LX, Harris J, De Ravin E, Balar E, Moreira AG, Rajasekaran K. Clinical
237		practice guidelines for pain management after tonsillectomy: Systematic quality
238		appraisal using the AGREE II instrument. Int J Pediatr Otorhinolaryngol
239		2022;156:111091.
240	11.	Ochs HR, Knüchel M, Abernethy DR, Greenblatt DJ. Dose-independent
241		pharmacokinetics of intravenous lidocaine in humans. J Clin Pharmacol 1983;23:186-
242		188.
243		